MedTrace Logo

The Clinical Features and Pregnancy Outcomes of RA Patients

NCT05651373 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-12-15

No results posted yet for this study

Summary

This study includes RA patients in pregnancy, who are using different treatment regimens，including prednisone, hydroxychloroquine, and/or TNF inhibitors. The maternal disease activity, pregnancy outcomes, maternal and fetal safety are assessing during the trimester of pregnancy. The effects of different therapies and risk factors for adverse pregnancy outcomes will be analysis.

Conditions

Interventions

DRUG

Prednisone

5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response

DRUG

Hydroxychloroquine

200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.

DRUG

CertolizumabPegol injection

200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Xiaoyun Yang · Qilu Hospital of Shandong University

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-30
Primary Completion
2023-08-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05651373 on ClinicalTrials.gov